Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

← catalyst calendar

NCT06337084

Sponsored by Monopar Therapeutics (industry) · MNPR — their whole pipeline →.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
12estimated
Sites
1
Country
Australia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-05-30actualWhen the study began enrolling
Primary completionApr 2026estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionApr 2026estimatedThe whole study's end, after follow-up
First posted2024-03-29actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-05-22actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Solid Tumor, Adult
  • Bladder Cancer
  • Urothelial Carcinoma
  • Triple-negative Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

Interventions

  • Drug: MNPR-101-DFO*-89Zr
  • Diagnostic test: PET/CT Diagnostic Imaging

Primary outcomes

what the primary-completion date above is the date OF
To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr
measured Post infusion at 2 h on Day 1, once on Days 3-5, and once on Days 7-10.
To assess tumor Standard Uptake Value (SUV) of MNPR-101-DFO*-89Zr
measured Post infusion at 2 h on Day 1, once on Days 3-5, and once on Days 7-10.
To assess safety of MNPR-101-DFO*-89Zr as assessed by CTCAE 5.0
measured Screening through Day 30 Safety Visit.

Permalink · MNPR's whole pipeline · Catalyst calendar · Every registered study · What changed